Cargando…
A three-country comparison of psychotropic medication prevalence in youth
BACKGROUND: The study aims to compare cross-national prevalence of psychotropic medication use in youth. METHODS: A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569908/ https://www.ncbi.nlm.nih.gov/pubmed/18817536 http://dx.doi.org/10.1186/1753-2000-2-26 |
_version_ | 1782160089198624768 |
---|---|
author | Zito, Julie M Safer, Daniel J Berg, Lolkje TW de Jong-van den Janhsen, Katrin Fegert, Joerg M Gardner, James F Glaeske, Gerd Valluri, Satish C |
author_facet | Zito, Julie M Safer, Daniel J Berg, Lolkje TW de Jong-van den Janhsen, Katrin Fegert, Joerg M Gardner, James F Glaeske, Gerd Valluri, Satish C |
author_sort | Zito, Julie M |
collection | PubMed |
description | BACKGROUND: The study aims to compare cross-national prevalence of psychotropic medication use in youth. METHODS: A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age group (0–4, 5–9, 10–14, and 15–19), gender, drug subclass pattern and concomitant use. The data include insured youth aged 0–19 in the year 2000 from the Netherlands (n = 110,944), Germany (n = 356,520) and the United States (n = 127,157). RESULTS: The annual prevalence of any psychotropic medication in youth was significantly greater in the US (6.7%) than in the Netherlands (2.9%) and in Germany (2.0%). Antidepressant and stimulant prevalence were 3 or more times greater in the US than in the Netherlands and Germany, while antipsychotic prevalence was 1.5–2.2 times greater. The atypical antipsychotic subclass represented only 5% of antipsychotic use in Germany, but 48% in the Netherlands and 66% in the US. The less commonly used drugs e.g. alpha agonists, lithium and antiparkinsonian agents generally followed the ranking of US>Dutch>German youth with very rare (less than 0.05%) use in Dutch and German youth. Though rarely used, anxiolytics were twice as common in Dutch as in US and German youth. Prescription hypnotics were half as common as anxiolytics in Dutch and US youth and were very uncommon in German youth. Concomitant drug use applied to 19.2% of US youth which was more than double the Dutch use and three times that of German youth. CONCLUSION: Prominent differences in psychotropic medication treatment patterns exist between youth in the US and Western Europe and within Western Europe. Differences in policies regarding direct to consumer drug advertising, government regulatory restrictions, reimbursement policies, diagnostic classification systems, and cultural beliefs regarding the role of medication for emotional and behavioral treatment are likely to account for these differences. |
format | Text |
id | pubmed-2569908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25699082008-10-18 A three-country comparison of psychotropic medication prevalence in youth Zito, Julie M Safer, Daniel J Berg, Lolkje TW de Jong-van den Janhsen, Katrin Fegert, Joerg M Gardner, James F Glaeske, Gerd Valluri, Satish C Child Adolesc Psychiatry Ment Health Research BACKGROUND: The study aims to compare cross-national prevalence of psychotropic medication use in youth. METHODS: A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age group (0–4, 5–9, 10–14, and 15–19), gender, drug subclass pattern and concomitant use. The data include insured youth aged 0–19 in the year 2000 from the Netherlands (n = 110,944), Germany (n = 356,520) and the United States (n = 127,157). RESULTS: The annual prevalence of any psychotropic medication in youth was significantly greater in the US (6.7%) than in the Netherlands (2.9%) and in Germany (2.0%). Antidepressant and stimulant prevalence were 3 or more times greater in the US than in the Netherlands and Germany, while antipsychotic prevalence was 1.5–2.2 times greater. The atypical antipsychotic subclass represented only 5% of antipsychotic use in Germany, but 48% in the Netherlands and 66% in the US. The less commonly used drugs e.g. alpha agonists, lithium and antiparkinsonian agents generally followed the ranking of US>Dutch>German youth with very rare (less than 0.05%) use in Dutch and German youth. Though rarely used, anxiolytics were twice as common in Dutch as in US and German youth. Prescription hypnotics were half as common as anxiolytics in Dutch and US youth and were very uncommon in German youth. Concomitant drug use applied to 19.2% of US youth which was more than double the Dutch use and three times that of German youth. CONCLUSION: Prominent differences in psychotropic medication treatment patterns exist between youth in the US and Western Europe and within Western Europe. Differences in policies regarding direct to consumer drug advertising, government regulatory restrictions, reimbursement policies, diagnostic classification systems, and cultural beliefs regarding the role of medication for emotional and behavioral treatment are likely to account for these differences. BioMed Central 2008-09-25 /pmc/articles/PMC2569908/ /pubmed/18817536 http://dx.doi.org/10.1186/1753-2000-2-26 Text en Copyright © 2008 Zito et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Zito, Julie M Safer, Daniel J Berg, Lolkje TW de Jong-van den Janhsen, Katrin Fegert, Joerg M Gardner, James F Glaeske, Gerd Valluri, Satish C A three-country comparison of psychotropic medication prevalence in youth |
title | A three-country comparison of psychotropic medication prevalence in youth |
title_full | A three-country comparison of psychotropic medication prevalence in youth |
title_fullStr | A three-country comparison of psychotropic medication prevalence in youth |
title_full_unstemmed | A three-country comparison of psychotropic medication prevalence in youth |
title_short | A three-country comparison of psychotropic medication prevalence in youth |
title_sort | three-country comparison of psychotropic medication prevalence in youth |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569908/ https://www.ncbi.nlm.nih.gov/pubmed/18817536 http://dx.doi.org/10.1186/1753-2000-2-26 |
work_keys_str_mv | AT zitojuliem athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT saferdanielj athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT berglolkjetwdejongvanden athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT janhsenkatrin athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT fegertjoergm athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT gardnerjamesf athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT glaeskegerd athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT vallurisatishc athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT zitojuliem threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT saferdanielj threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT berglolkjetwdejongvanden threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT janhsenkatrin threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT fegertjoergm threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT gardnerjamesf threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT glaeskegerd threecountrycomparisonofpsychotropicmedicationprevalenceinyouth AT vallurisatishc threecountrycomparisonofpsychotropicmedicationprevalenceinyouth |